A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3

Berger, Rolf M F; Gehin, Martine; Beghetti, Maurice; Ivy, Dunbar; Kusic-Pajic, Andjela; Cornelisse, Peter; Grill, Simon; Bonnet, Damien

doi:10.1111/bcp.13267

Scientific article

English

A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3

ContributorsBerger, Rolf M F; Gehin, Martine; Beghetti, Maurice; Ivy, Dunbar; Kusic-Pajic, Andjela; Cornelisse, Peter; Grill, Simon; Bonnet, Damien

Published inBritish Journal of Clinical Pharmacology, vol. 83, no. 8, p. 1734-1744

Publication date2017

Abstract

The aim of the present study was to investigate whether increasing the bosentan dosing frequency from 2 mg kg-1 twice daily (b.i.d.) to 2 mg kg-1 three times daily (t.i.d.) in children with pulmonary arterial hypertension (PAH) (from ≥3 months to <12 years of age) would increase exposure.

Keywords

Administration
Oral
Antihypertensive Agents/pharmacokinetics/therapeutic use
Area Under Curve
Child
Child
Preschool
Dose-Response Relationship
Drug
Drug Administration Schedule
Endothelin Receptor Antagonists/pharmacokinetics/therapeutic use
Female
Humans
Hypertension
Pulmonary/drug therapy
Infant
Male
Prospective Studies
Sulfonamides/pharmacokinetics/therapeutic use

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de pédiatrie, gynécologie et obstétrique

Research groups

L'hypertension pulmonaire (pédiatrie) (228)

Citation (ISO format)

BERGER, Rolf M F et al. A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3. In: British Journal of Clinical Pharmacology, 2017, vol. 83, n° 8, p. 1734–1744. doi: 10.1111/bcp.13267

Article (Published version)

CC BY-NC-SA

Identifiers

PID : unige:107597
DOI : 10.1111/bcp.13267
PMID : 28213957

Journal ISSN0306-5251

580views

300downloads

Creation05/09/2018 12:24:00

First validation05/09/2018 12:24:00

Update15/03/2023 08:37:11

Status update15/03/2023 08:37:10

Last indexation31/10/2024 11:01:21

Archive ouverte UNIGE

A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3

The aim of the present study was to investigate whether increasing the bosentan dosing frequency from 2 mg kg-1 twice daily (b.i.d.) to 2 mg kg-1 three times daily (t.i.d.) in children with pulmonary arterial hypertension (PAH) (from ≥3 months to <12 years of age) would increase exposure.

Technical informations